Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism

Cancer Research

Volumn 69, Issue 3, 2009, Pages 1212-1220

  Kaur, Balveen ^a,c   Cork, Sarah M ^a   Sandberg, Eric M ^a   Devi, Narra S ^a   Zhang, Zhaobin ^a   Klenotic, Philip A ^b   Febbraio, Maria ^b   Shim, Hyunsuk ^a   Mao, Hui ^a   Tucker Burden, Carol ^a   Silverstein, Roy L ^b   Brat, Daniel J ^a   Olson, Jeffrey J ^a   Van Meir, Erwin G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOSTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; DRUG INHIBITION; ENDOTHELIUM CELL; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULARIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT; RAT; TUMOR GROWTH;

ANGIOGENIC PROTEINS; ANIMALS; ANTIGENS, CD36; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CORNEAL NEOVASCULARIZATION; DNA, COMPLEMENTARY; ENDOTHELIAL CELLS; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; RATS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 59149099562     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1166     Document Type: Article

References (50)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Wang D, Anderson JC, Gladson CL. The role of the extracellular matrix in angiogenesis in malignant glioma tumors. Brain Pathol 2005;15:318-26.
3. Tenan M, Fulci G, Albertoni M, et al. Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells. J Exp Med 2000;191:1789-98.
4. Desbaillets I, Diserens AC, Tribolet N, Hamou MF, Van Meir EG. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 1997;186:1201-12.
5. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
6. Kurozumi K, Hardcastle J, Thakur R, et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 2007;99:1768-81.
7. Brat DJ, Castellano-Sanchez AA, Hunter SB, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004;64:920-7.
8. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
9. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001;93:1246-56.
10. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 1992;89:4309-13.
11. Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985;313:144-7.
12. Shiratsuchi T, Futamura M, Oda K, et al. Cloning and characterization of BAI-associated protein 1: a PDZ domain-containing protein that interacts with BAI1. Biochem Biophys Res Commun 1998;247:597-604.
13. Nishimori H, Shiratsuchi T, Urano T, et al. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 1997;15:2145-50.
14. Kaur B, Brat DJ, Calkins CC, Van Meir EG. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol 2003;162:19-27.
15. Hatanaka H, Oshika Y, Abe Y, et al. Vascularization is decreased in pulmonary adenocarcinoma expressing brain-specific angiogenesis inhibitor 1 (BAI1). Int J Mol Med 2000;5:181-3.
16. Fukushima Y, Oshika Y, Tsuchida T, et al. Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer. Int J Oncol 1998;13:967-70.
17. Kudo S, Konda R, Obara W, et al. Inhibition of tumor growth through suppression of angiogenesis by brainspecific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma. Oncol Rep 2007;18:785-91.
18. Kang X, Xiao X, Harata M, et al. Antiangiogenic activity of BAI1 in vivo : implications for gene therapy of human glioblastomas. Cancer Gene Ther 2006;13:385-92.
19. Kaur B, Brat DJ, Devi NS, Van Meir EG. Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 2005;24:3632-42.
20. Maubant S, Saint-Dizier D, Boutillon M, et al. Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 2006;108:3035-44.
21. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-57.
22. Sun X, Skorstengaard K, Mosher DF. Disulfides modulate RGD-inhibitable cell adhesive activity of thrombospondin. J Cell Biol 1992;118:693-701.
23. Blouw B, Song H, Tihan T, et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003;4:133-46.
24. Mori K, Kanemura Y, Fujikawa H, et al. Brain-specific angiogenesis inhibitor 1 (BAI1) is expressed in human cerebral neuronal cells. Neurosci Res 2002;43:69-74.
25. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9:469-79.
26. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994;91:7727-31.
27. Pearce SF, Roy P, Nicholson AC, et al. Recombinant glutathione S-transferase/CD36 fusion proteins define an oxidized low density lipoprotein-binding domain. J Biol Chem 1998;273:34875-81.
28. Hudziak RM, Lewis GD, Winget M, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-72.
29. Van Meir EG. Identification of nude mice in tumorigenicity assays. Int J Cancer 1997;71:310.
30. Bowers G, He J, Schulz K, et al. Efficacy of adenoviral p53 delivery with SCH58500 in the intracranial 9l and RG2 models. Front Biosci 2003;8:a54-61.
31. Kenyon BM, Voest EE, Chen CC, et al. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996;37:1625-32.
32. Wen S, Stolarov J, Myers MP, et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A 2001;98:4622-7.
33. Abe T, Terada K, Wakimoto H, et al. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res 2003;63:2300-5.
34. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol 2004;36:961-8.
35. Dawson DW, Pearce SF, Zhong R, et al. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997;138:707-17.
36. Swerlick RA, Lee KH, Wick TM, Lawley TJ. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro . J Immunol 1992;148:78-83.
37. Simantov R, Silverstein RL. Cd36: a critical anti-angiogenic receptor. Front Biosci 2003;8:S874-82.
38. Jimenez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6:41-8.
39. Koh JT, Kook H, Kee HJ, et al. Extracellular fragment of brain-specific angiogenesis inhibitor 1 suppresses endothelial cell proliferation by blocking αvβ5 integrin. Exp Cell Res 2004;294:172-84.
40. de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG. Thrombospondins and tumor angiogenesis. Trends Mol Med 2001;7:401-7.
41. Nicholson AC, Malik SB, Logsdon JM, Jr., Van Meir EG. Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization. BMC Evol Biol 2005;5:11.
42. Tan K, Duquette M, Liu JH, et al. Heparin-induced cis- and trans- dimerization modes of the thrombospondin-1 N-terminal domain. J Biol Chem 2007;283:3932-41.
43. Park D, Tosello-Trampont AC, Elliott MR, et al. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 2007;450:430-4.
44. Anderson JC, Grammer JR, Wang W, et al. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 2007;6:454-62.
45. Crombie R, Silverstein RL, MacLow C, et al. Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva. J Exp Med 1998;187:25-35.
46. Crombie R, Silverstein R. Lysosomal integral membrane protein II binds thrombospondin-1. Structure-function homology with the cell adhesion molecule CD36 defines a conserved recognition motif. J Biol Chem 1998;273:4855-63.
47. Rusk A, McKeegan E, Haviv F, et al. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 2006;12:7444-55.
48. Markovic SN, Suman VJ, Rao RA, et al. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 2007;30:303-9.
49. Kurozumi K, Hardcastle J, Thakur R, et al. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 2008;16:1382-91.
50. Post DE, Devi NS, Li Z, et al. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 2004;10:8603-12.